Compare Stocks: CRNX, RPRX, ZTS, and VTRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$84.72 0.0%	$66.01	$28.73 ▼ $84.80	$8.98B	0.12	2.61 million shs	3.97 million shs
RPRX Royalty Pharma	$59.69 +0.4%	$56.99	$34.08 ▼ $60.44	$33.70B	0.43	2.87 million shs	2.07 million shs
VTRS Viatris	$16.17 -0.4%	$16.59	$9.43 ▼ $18.39	$18.64B	0.9	11.20 million shs	9.05 million shs
ZTS Zoetis	$74.04 +1.5%	$76.01	$71.00 ▼ $160.48	$30.49B	0.73	6.89 million shs	4.03 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	-0.04%	+0.43%	+1.03%	+133.58%	+184.87%
RPRX Royalty Pharma	+0.40%	+3.29%	+2.60%	+12.50%	+66.17%
VTRS Viatris	-0.37%	-0.68%	-6.48%	-2.53%	+52.12%
ZTS Zoetis	+1.83%	-1.58%	-3.14%	-7.03%	-51.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$84.72 0.0%	$66.01	$28.73 ▼ $84.80	$8.98B	0.12	2.61 million shs	3.97 million shs
RPRX Royalty Pharma	$59.69 +0.4%	$56.99	$34.08 ▼ $60.44	$33.70B	0.43	2.87 million shs	2.07 million shs
VTRS Viatris	$16.17 -0.4%	$16.59	$9.43 ▼ $18.39	$18.64B	0.9	11.20 million shs	9.05 million shs
ZTS Zoetis	$74.04 +1.5%	$76.01	$71.00 ▼ $160.48	$30.49B	0.73	6.89 million shs	4.03 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	-0.04%	+0.43%	+1.03%	+133.58%	+184.87%
RPRX Royalty Pharma	+0.40%	+3.29%	+2.60%	+12.50%	+66.17%
VTRS Viatris	-0.37%	-0.68%	-6.48%	-2.53%	+52.12%
ZTS Zoetis	+1.83%	-1.58%	-3.14%	-7.03%	-51.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.39% Downside
RPRX Royalty Pharma	3.00	Buy	$60.86	1.96% Upside
VTRS Viatris	2.57	Moderate Buy	$17.50	8.23% Upside
ZTS Zoetis	2.32	Hold	$109.62	48.04% Upside

Current Analyst Ratings Breakdown

Latest CRNX, RPRX, ZTS, and VTRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	RPRX Royalty Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
8/11/2026	ZTS Zoetis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$112.00 ➝ $96.00
8/11/2026	ZTS Zoetis	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$146.00 ➝ $110.00
8/10/2026	ZTS Zoetis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/10/2026	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$90.00 ➝ $80.00
8/7/2026	ZTS Zoetis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$85.00
8/7/2026	RPRX Royalty Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$58.00 ➝ $62.00
8/7/2026	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$85.00 ➝ $80.00
8/7/2026	ZTS Zoetis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$130.00 ➝ $115.00
8/6/2026	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/6/2026	RPRX Royalty Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$66.00

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRNX Crinetics Pharmaceuticals	$7.70M	1,167.05	N/A	N/A	$9.71 per share	8.73
RPRX Royalty Pharma	$2.38B	14.43	$4.86 per share	12.27	$16.83 per share	3.55
VTRS Viatris	$14.30B	1.30	$7.35 per share	2.20	$12.77 per share	1.27
ZTS Zoetis	$9.47B	3.23	$7.59 per share	9.75	$7.56 per share	9.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
RPRX Royalty Pharma	$770.95M	$1.45	41.17	10.79	1.37	32.14%	30.01%	14.91%	11/4/2026 (Estimated)
VTRS Viatris	-$3.51B	-$0.36	N/A	6.08	1.46	-2.79%	20.02%	8.02%	11/5/2026 (Estimated)
ZTS Zoetis	$2.67B	$6.07	12.20	11.29	1.28	27.49%	74.89%	18.59%	11/3/2026 (Estimated)

Latest CRNX, RPRX, ZTS, and VTRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	VTRS Viatris	$0.6010	$0.69	+$0.0890	-$0.10	$3.68 billion	$3.76 billion
8/6/2026	Q2 2026	ZTS Zoetis	$1.85	$1.87	+$0.02	$1.65	$2.50 billion	$2.47 billion
8/5/2026	Q2 2026	RPRX Royalty Pharma	$1.27	$1.32	+$0.05	$0.04	$758.93 million	$674.14 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.94	1.57%	+24.01%	64.83%	5 Years
VTRS Viatris	$0.48	2.97%	N/A	N/A	N/A
ZTS Zoetis	$2.12	2.86%	+20.11%	34.93%	14 Years

Latest CRNX, RPRX, ZTS, and VTRS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/3/2026	VTRS Viatris	quarterly	$0.12	2.71%	8/21/2026	8/21/2026	9/16/2026
7/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.6%	8/14/2026	8/14/2026	9/10/2026
5/20/2026	ZTS Zoetis	quarterly	$0.53	2.78%	7/20/2026	7/20/2026	9/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
RPRX Royalty Pharma	0.88	2.80	2.80
VTRS Viatris	0.81	1.58	0.96
ZTS Zoetis	2.87	3.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRNX Crinetics Pharmaceuticals	98.51%
RPRX Royalty Pharma	54.35%
VTRS Viatris	79.88%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
CRNX Crinetics Pharmaceuticals	3.80%
RPRX Royalty Pharma	18.84%
VTRS Viatris	0.28%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRNX Crinetics Pharmaceuticals	210	106.07 million	102.04 million	Optionable
RPRX Royalty Pharma	80	575.00 million	466.67 million	Optionable
VTRS Viatris	30,000	1.15 billion	1.15 billion	Optionable
ZTS Zoetis	14,500	413.22 million	412.32 million	Optionable

CRNX, RPRX, ZTS, and VTRS Headlines

Recent News About These Companies

Mitsubishi UFJ Asset Management Co. Ltd. Has $76.91 Million Stake in Zoetis Inc. $ZTS

21 minutes ago | marketbeat.com

BlackRock Inc. Grows Position in Zoetis Inc. $ZTS

2 hours ago | marketbeat.com

Michael Burry is Bullish on This Beaten-Down Healthcare Stock. Time to Buy?

August 18 at 11:10 AM | insidermonkey.com

Zoetis Inc. $ZTS Shares Bought by Texas Capital Bank Wealth Management Services Inc

August 18 at 6:31 AM | marketbeat.com

Zoetis: A Solid Long-Term Buy After Harsh Drawdown

August 18 at 4:50 AM | seekingalpha.com

Deutsche Bank AG Purchases 319,709 Shares of Zoetis Inc. $ZTS

August 18 at 4:24 AM | marketbeat.com

18,470 Shares in Zoetis Inc. $ZTS Purchased by GSA Capital Partners LLP

August 18 at 4:07 AM | marketbeat.com

Flputnam Investment Management Co. Raises Stock Position in Zoetis Inc. $ZTS

August 18 at 4:01 AM | marketbeat.com

Zoetis (NYSE:ZTS) Hits New 52-Week Low - Here's Why

August 17 at 12:59 PM | marketbeat.com

Diamond Hill Capital Management LLC Investment Advisor Purchases 629,974 Shares of Zoetis Inc. $ZTS

August 17 at 4:16 AM | marketbeat.com

Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap

August 16 at 8:51 AM | seekingalpha.com

Russell Investments Group Ltd. Has $64.44 Million Stock Holdings in Zoetis Inc. $ZTS

August 16 at 6:47 AM | marketbeat.com

Mitsubishi UFJ Trust & Banking Corp Sells 14,700 Shares of Zoetis Inc. $ZTS

August 16 at 6:31 AM | marketbeat.com

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Lowers Stock Position in Zoetis Inc. $ZTS

August 16 at 6:31 AM | marketbeat.com

Zoetis Inc. $ZTS Stock Holdings Increased by Moran Wealth Management LLC

August 16 at 6:23 AM | marketbeat.com

SFE Investment Counsel Has $332,000 Holdings in Zoetis Inc. $ZTS

August 16 at 6:23 AM | marketbeat.com

KBC Group NV Acquires 16,375 Shares of Zoetis Inc. $ZTS

August 16 at 6:16 AM | marketbeat.com

Janney Montgomery Scott LLC Sells 93,748 Shares of Zoetis Inc. $ZTS

August 16 at 6:15 AM | marketbeat.com

Capital Analysts LLC Trims Stock Position in Zoetis Inc. $ZTS

August 16 at 4:23 AM | marketbeat.com

HighTower Advisors LLC Has $18.21 Million Stock Holdings in Zoetis Inc. $ZTS

August 16 at 4:23 AM | marketbeat.com

Fifth Third Bancorp Decreases Stake in Zoetis Inc. $ZTS

August 16 at 4:07 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX, RPRX, ZTS, and VTRS Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.72 -0.03 (-0.04%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$84.72 0.00 (0.00%)

As of 08/18/2026 07:56 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Royalty Pharma NASDAQ:RPRX

$59.69 +0.24 (+0.40%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$60.09 +0.40 (+0.67%)

As of 04:33 AM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Viatris NASDAQ:VTRS

$16.17 -0.06 (-0.37%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$16.18 +0.01 (+0.06%)

As of 05:24 AM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Zoetis NYSE:ZTS

$74.04 +1.07 (+1.47%)

Closing price 08/18/2026 03:59 PM Eastern

Extended Trading

$74.19 +0.15 (+0.20%)

As of 06:00 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRNX, RPRX, ZTS, and VTRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRNX, RPRX, ZTS, and VTRS Earnings

Compare Dividends

Latest CRNX, RPRX, ZTS, and VTRS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRNX, RPRX, ZTS, and VTRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX, RPRX, ZTS, and VTRS Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

Royalty Pharma NASDAQ:RPRX

Viatris NASDAQ:VTRS

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRNX, RPRX, ZTS, and VTRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRNX, RPRX, ZTS, and VTRS Earnings

Compare Dividends

Latest CRNX, RPRX, ZTS, and VTRS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRNX, RPRX, ZTS, and VTRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX, RPRX, ZTS, and VTRS Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

Royalty Pharma NASDAQ:RPRX

Viatris NASDAQ:VTRS

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools